Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Lam Research
LRCX
|
$792M |
| 2 |
Johnson & Johnson
JNJ
|
$659M |
| 3 |
Datadog
DDOG
|
$571M |
| 4 |
Amazon
AMZN
|
$474M |
| 5 |
Broadcom
AVGO
|
$458M |
Top Sells
| 1 |
Workday
WDAY
|
$1.23B |
| 2 |
AbbVie
ABBV
|
$1.03B |
| 3 |
Advanced Micro Devices
AMD
|
$686M |
| 4 |
Honeywell
HON
|
$673M |
| 5 |
Amgen
AMGN
|
$620M |
Sector Composition
| 1 | Technology | 34.72% |
| 2 | Healthcare | 17.58% |
| 3 | Consumer Discretionary | 10.69% |
| 4 | Financials | 10.22% |
| 5 | Communication Services | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Zurn Elkay Water Solutions
ZWS
$7.71B
| $149M | 0.08% |
4,006,596
+245,258
| +7% | +$9.15M |
|
227
Teva Pharmaceuticals
TEVA
$21.7B
| $148M | 0.08% |
6,737,625
+1,945,688
| +41% | +$42.9M |
|
|
AVDL
228
Avadel Pharmaceuticals
AVDL
$1.53B
| $148M | 0.08% |
14,080,219
+753,332
| +6% | +$7.92M |
|
229
CCC Intelligent Solutions
CCCS
$6.4B
| $147M | 0.07% |
12,553,813
+4,583
| +0% | +$53.8K |
|
|
SARO
230
StandardAero, Inc.
SARO
$8.88B
| $146M | 0.07% |
+5,890,511
| New | +$146M |
|
231
Realty Income
O
$54.2B
| $146M | 0.07% |
2,725,360
-34,822
| -1% | -$1.86M |
|
232
Mirion Technologies
MIR
$5.28B
| $145M | 0.07% |
8,330,495
+229,718
| +3% | +$4.01M |
|
233
Crinetics Pharmaceuticals
CRNX
$3.35B
| $143M | 0.07% |
2,795,441
+365,991
| +15% | +$18.7M |
|
234
Euronet Worldwide
EEFT
$3.74B
| $143M | 0.07% |
1,386,382
+20,805
| +2% | +$2.14M |
|
235
Penumbra
PEN
$11B
| $142M | 0.07% |
597,077
-71,796
| -11% | -$17.1M |
|
236
United Parcel Service
UPS
$72.1B
| $142M | 0.07% |
1,122,886
+853,388
| +317% | +$108M |
|
237
Dollar Tree
DLTR
$20.6B
| $139M | 0.07% |
1,853,432
+8,670
| +0.5% | +$650K |
|
238
WEC Energy
WEC
$34.7B
| $138M | 0.07% |
1,471,096
+1,433,522
| +3,815% | +$135M |
|
239
Vanguard Total International Stock ETF
VXUS
$102B
| $137M | 0.07% |
2,330,013
-49,338
| -2% | -$2.91M |
|
240
Gates Industrial
GTES
$6.68B
| $135M | 0.07% |
6,569,959
+85,253
| +1% | +$1.75M |
|
241
RTX Corp
RTX
$211B
| $135M | 0.07% |
1,166,464
+189,937
| +19% | +$22M |
|
242
BridgeBio Pharma
BBIO
$10.2B
| $135M | 0.07% |
4,907,533
+89,521
| +2% | +$2.46M |
|
243
Bristol-Myers Squibb
BMY
$96B
| $134M | 0.07% |
2,375,593
-1,179,165
| -33% | -$66.7M |
|
244
Elevance Health
ELV
$70.6B
| $134M | 0.07% |
363,526
-22,878
| -6% | -$8.44M |
|
245
AstraZeneca
AZN
$253B
| $134M | 0.07% |
2,044,259
+374,705
| +22% | +$24.6M |
|
246
Edgewise Therapeutics
EWTX
$1.64B
| $133M | 0.07% |
4,983,940
+425,421
| +9% | +$11.4M |
|
247
ITT
ITT
$13.3B
| $133M | 0.07% |
928,116
+11,980
| +1% | +$1.71M |
|
248
Marriott International Class A Common Stock
MAR
$71.9B
| $131M | 0.07% |
469,239
-143,813
| -23% | -$40.1M |
|
249
89bio
ETNB
$1.32B
| $129M | 0.07% |
16,514,056
+1,355,838
| +9% | +$10.6M |
|
250
Public Storage
PSA
$52.2B
| $129M | 0.07% |
431,129
+29,972
| +7% | +$8.97M |
|